# Vietnam Pharmaceutical Market Outlook to 2027 --- ## Market Overview # CHAPTER 1 - Market Overview The Vietnam Pharmaceutical Market functions as a reimbursement-sensitive, hospital-led healthcare market in which prescription demand drives the revenue pool and OTC acts as a secondary access channel. In 2024, health insurance coverage reached **94.2% of the population**, while the ETC channel accounted for about **76% of market revenue**. Commercially, this means tender access, formulary inclusion, and chronic refill compliance matter more than pure retail shelf presence for scale players. Ho Chi Minh City remains the most important operating hub because manufacturing, wholesale, and pharmacy density are concentrated there. City health authorities reported **43 drug manufacturing factories**, **1,512 wholesalers and pharmaceutical raw-material trading facilities**, and **8,387 pharmacies** in 2023. Economically, that cluster shortens launch cycles, improves field-force productivity, and makes the city the primary node for ETC distribution, private retail sell-out, and medical representative deployment. Regulation shapes both price realization and market access. Circular **07/2024/TT-BYT**, effective from **May 17, 2024**, reset drug procurement rules for public health facilities and allows framework agreement and bidding-package implementation periods of up to **36 months**. For suppliers, the effect is twofold: longer visibility on awarded volume, but tighter scrutiny on quality tiers, bid compliance, and price discipline in the public channel where revenue concentration is highest. The market is moving toward higher domestic capability, but trade dependence is still material. In the first six months of 2024, Vietnam’s pharmaceutical imports reached **USD 1,997.99 Mn**, up **24.1%** year on year, even as domestic producers supplied nearly **50% of drug-use value** and close to **70% of quantity** by 2022. For investors, this combination supports two parallel theses: import-substitution manufacturing and premium imported-therapy commercialization. ## KPIs at a Glance * Market Value: USD 7,700 Mn (2024) * Dominant Region: Ho Chi Minh City (2024) * Dominant Segment: Generic Drugs (Small-Molecule, Domestic-Manufactured) (2024) * Total Number of Players: 238 (2023) ## Future Outlook The Vietnam Pharmaceutical Market is projected to maintain structurally strong expansion from its **USD 7,700 Mn** base in 2024, supported by broad insurance coverage, rising chronic-disease treatment intensity, and a gradual shift toward higher-value specialty therapies. The historical growth trajectory remains robust, with the market estimated to have expanded at a **9.6% CAGR during 2019-2024**. That period combined wider access, stronger domestic manufacturing participation, and post-pandemic normalization of hospital procurement. Looking ahead, the operating model becomes more quality-sensitive, because growth is increasingly captured through reimbursed specialty portfolios, compliant bidding participation, and production upgrades that support better pricing power and lower import substitution risk. For 2025-2030, the Vietnam Pharmaceutical Market is forecast to grow at an **8.0% CAGR**, reaching approximately **USD 12,226 Mn by 2030**. The slower but still elevated pace versus 2019-2024 reflects a larger base, tighter public procurement discipline, and continued import exposure in innovator therapies. Even so, the mix is improving: oncology, specialty medicines, vaccines, and biologics should outgrow mass-market herbal and low-complexity products. Strategically, this supports investment in EU-GMP and PIC/S upgrades, hospital-market access capabilities, and omni-channel pharmacy models rather than volume-only expansion. Forecast risk remains concentrated in procurement timing, registration cycles, and foreign-currency-linked raw material costs. --- | | | | --- | --- | | **8.0%** Forecast CAGR | **$12,226 Mn** 2030 Projection | --- | | | | | | --- | --- | --- | --- | | Base Year **2024** | Historical Period **2019-2024** | Forecast Period **2025-2030** | Historical CAGR **9.6%** | --- ## Scope of the Report # CHAPTER 2 - Scope of the Market ### Segmentation Data Tree * **By Type of Therapeutic Drug** + Metabolism & Nutritional Medicine + Cardiovascular + System Infection + CNS + Oncology + Respiratory + Musculoskeletal + Others * **By Purchase Channel** + ETC (Prescription Drugs) + OTC * **By type of Freight End Users** + Retail + Automobile + Pharma + Others * **By Type of Drug** + Generic Drug + Patented Drug * **By Sales Channel** + Hospitals & Hospital owned Pharmacy + Individual Drug Stores & retailers * **By Sales Mode** + Offline + Online --- ## Market Trajectory # Market Size, Growth Forecast and Trends This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers. | Year | Market Size (USD Mn) | | --- | --- | | 2019 | 4,875 | | 2020 | 5,205 | | 2021 | 5,750 | | 2022 | 6,365 | | 2023 | 7,072 | | 2024 | 7,700 | | 2025F | 8,316 | | 2026F | 8,981 | | 2027F | 9,700 | | 2028F | 10,476 | | 2029F | 11,320 | | 2030F | 12,226 | | Year | YoY Growth (%) | | --- | --- | | 2020 | 6.8% | | 2021 | 10.5% | | 2022 | 10.7% | | 2023 | 11.1% | | 2024 | 8.9% | | 2025F | 8.0% | | 2026F | 8.0% | | 2027F | 8.0% | | 2028F | 8.0% | | 2029F | 8.1% | | 2030F | 8.0% | | Year | Market Value Growth (%) | Market Volume Growth (%) | | --- | --- | --- | | 2019 | - | - | | 2020 | 6.8% | 4.1% | | 2021 | 10.5% | 6.2% | | 2022 | 10.7% | 6.8% | | 2023 | 11.1% | 5.8% | | 2024 | 8.9% | 6.1% | | 2025 | 8.0% | 6.8% | | 2026 | 8.0% | 6.8% | | 2027 | 8.0% | 6.9% | | 2028 | 8.0% | 6.9% | | 2029 | 8.1% | 6.8% | ### Historical Market Performance (2019-2024) The Vietnam Pharmaceutical Market added **USD 2,825 Mn** between 2019 and 2024, while market volume rose from **3,660 MSUs** to **4,850 MSUs**. Per capita pharmaceutical spend increased from **USD 50.5** to **USD 76.2**, showing that growth was not only access-led but also supported by richer product mix. The trough year was **2020** with **6.8%** growth, while the strongest expansion occurred in **2023** at **11.1%**, reflecting normalized hospital tender execution and stronger chronic-care refill intensity. ETC concentration continued to favor companies with hospital-channel depth over purely retail-led portfolios. ### Forecast Market Outlook (2025-2030) From 2025 to 2030, the Vietnam Pharmaceutical Market is projected to reach **USD 12,226 Mn**, equivalent to an **8.0% CAGR**. Market volume is expected to rise to **7,210 MSUs** by 2030, but value will outpace volume as implied revenue per standard unit improves from **USD 1.59** in 2024 to **USD 1.70** in 2030. ETC share is expected to edge from **76.0%** to **77.5%**, indicating deeper reimbursement penetration. The strongest acceleration should remain concentrated in oncology, specialty medicines, and biologics rather than low-complexity self-medication categories. --- ## Market Breakdown # CHAPTER 4 - Market Breakdown The Vietnam Pharmaceutical Market is moving from broad-based access expansion toward a more mix-driven growth model. For CEOs and investors, the core question is no longer only volume growth, but which operating KPIs best explain pricing quality, channel concentration, and revenue capture over the 2019-2030 horizon. | Year | Market Size (USD Mn) | YoY Growth (%) | Market Volume (MSU) | Per Capita Pharma Spend (USD) | ETC Channel Share (%) | Period | | --- | --- | --- | --- | --- | --- | --- | | 2019 | 4,875 | - | 3,660 | 50.5 | 74.0% | Historical | | 2020 | 5,205 | 6.8% | 3,810 | 53.5 | 74.5% | Historical | | 2021 | 5,750 | 10.5% | 4,045 | 58.6 | 75.0% | Historical | | 2022 | 6,365 | 10.7% | 4,320 | 64.2 | 75.2% | Historical | | 2023 | 7,072 | 11.1% | 4,570 | 70.5 | 75.5% | Historical | | 2024 | 7,700 | 8.9% | 4,850 | 76.2 | 76.0% | Base Year | | 2025 | 8,316 | 8.0% | 5,180 | 81.6 | 76.3% | Forecast and Latest Operating KPIs | | 2026 | 8,981 | 8.0% | 5,530 | 87.4 | 76.6% | Forecast and Industry Outlook | | 2027 | 9,700 | 8.0% | 5,910 | 93.7 | 76.8% | Forecast and Industry Outlook | | 2028 | 10,476 | 8.0% | 6,320 | 100.5 | 77.0% | Forecast and Industry Outlook | | 2029 | 11,320 | 8.1% | 6,750 | 107.9 | 77.2% | Forecast and Industry Outlook | | 2030 | 12,226 | 8.0% | 7,210 | 115.8 | 77.5% | Forecast and Industry Outlook | **KPI 1, Market Volume:** **4,850 MSUs, 2024, Vietnam**. Volume growth confirms that demand expansion is still broad-based, not limited to premium products. Domestic production has already reached nearly 70% of drug-use quantity, which supports local generic scale economics and lower logistics friction. **KPI 2, Per Capita Pharma Spend:** **USD 76.2, 2024, Vietnam**. Rising spend per person shows improving treatment intensity and richer therapeutic mix. Vietnam’s population reached 101.1 million in 2024 and the share of population aged 60+ rose to 14.0%, supporting structurally higher chronic-care demand. **KPI 3, ETC Channel Share:** **76.0%, 2024, Vietnam**. This channel concentration means tender execution, reimbursement access, and hospital detailing remain central to value capture. Circular 07/2024/TT-BYT introduced public-sector drug bidding rules with framework agreements and bidding packages capped at 36 months. --- --- ## Market Segmentation # CHAPTER 5 - Market Segmentation Framework Comprehensive analysis across key market segmentation dimensions providing insights into market structure, revenue pools, buyer behavior, and distribution patterns. | | | | | --- | --- | --- | | **No of Segments:** 6 | **Dominant Segment:** By Purchase Channel | **Fastest Growing Segment:** By Sales Mode | ### S1: By Type of Therapeutic Drug This segment classifies revenue by therapeutic application; it is commercially relevant because disease burden determines prescribing intensity, with Metabolism & Nutritional Medicine dominant. * Metabolism & Nutritional Medicine: 18% * Cardiovascular: 15% * System Infection: 14% * CNS: 10% * Oncology: 12% * Respiratory: 9% * Musculoskeletal: 8% * Others: 14% ### S2: By Purchase Channel This segment captures how medicines are procured and reimbursed; it matters because ETC determines volume visibility and procurement discipline, with ETC dominant. * ETC (Prescription Drugs): 76% * OTC: 24% ### S3: By type of Freight End Users This segment reflects end-user demand destinations within the source taxonomy; it matters because Pharma users concentrate higher-value handling and regulated distribution economics. * Retail: 24% * Automobile: 8% * Pharma: 58% * Others: 10% ### S4: By Type of Drug This segment separates molecules by intellectual-property and pricing structure; it is commercially relevant because Generic Drug drives affordability and public tender participation. * Generic Drug: 72% * Patented Drug: 28% ### S5: By Sales Channel This segment maps where product is dispensed commercially; it matters because hospitals anchor prescription conversion and institutional revenue capture, with hospital-owned channels dominant. * Hospitals & Hospital owned Pharmacy: 68% * Individual Drug Stores & retailers: 32% ### S6: By Sales Mode This segment tracks transaction format and fulfillment behavior; it matters because offline scale dominates today, while online adds future acquisition and refill efficiency. * Offline: 97% * Online: 3% ### Key Segmentation Takeaways Comprehensive analysis across all segmentation dimensions providing insights into market structure, buyer preferences, revenue concentration, and distribution patterns. **By Purchase Channel** - This is the most commercially dominant segmentation axis because prescription demand in Vietnam is still centered on reimbursed care pathways, hospital formularies, and structured public procurement. ETC remains the core revenue pool for scale players, favors compliant manufacturers and hospital-focused distributors, and reinforces the importance of tender execution, field-force coverage, and stable supply to public institutions. **By Sales Mode** - This is the fastest-growing segmentation axis because digital commerce, online search behavior, and organized pharmacy integration are expanding faster than legacy dispensing models. Although offline remains structurally dominant, online formats are becoming strategically important for repeat purchases, chronic-care refill convenience, and consumer health acquisition, especially for urban pharmacy chains and digitally enabled distributors. --- ## Regional Analysis # Regional Analysis On the peer set used in this report, Vietnam ranks as the second-largest pharmaceutical market among the selected ASEAN comparables, behind Indonesia and ahead of Thailand. Its position is supported by a large insured population base, strong ETC channel depth, and a faster specialty-mix upgrade than most neighboring peers. ### KPI Summary * Regional Ranking: **2nd** * Vietnam Market Size (2024): **USD 7,700 Mn** * Vietnam CAGR (2025-2030): **8.0%** | Country | Market Size | CAGR (%) | Pharmaceutical Spend per Capita (USD) | Domestic Production Share (% of Market Value) | | --- | --- | --- | --- | --- | | Indonesia | USD 10,800 Mn | 7.1% | 38 | 26% | | Vietnam | USD 7,700 Mn | 8.0% | 76 | 49% | | Thailand | USD 6,800 Mn | 4.9% | 95 | 32% | | Philippines | USD 6,100 Mn | 6.7% | 53 | 35% | | Malaysia | USD 4,300 Mn | 5.8% | 126 | 24% | ### Market Position Vietnam ranks second in this peer set at **USD 7,700 Mn in 2024**, supported by **101.1 million** people and a prescription-led demand structure anchored by insurance coverage. ### Growth Advantage Vietnam’s **8.0% CAGR** outpaces Thailand at **4.9%** and Malaysia at **5.8%**, placing it among the stronger medium-term ASEAN growth markets. ### Competitive Strengths Vietnam combines **94.2% insurance coverage**, nearly **50% domestic value supply**, and a policy target to lift higher-standard manufacturing capacity, creating a stronger scale-to-localization pathway than several peers. Comprehensive analysis of key factors shaping the market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments. --- ## Growth Drivers ### Growth Drivers, Challenges & Opportunities Comprehensive analysis of key factors shaping the Vietnam Pharmaceutical Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments. ## Growth Drivers ### Insurance-backed chronic-care expansion Prescription demand is reinforced by **94.2% health insurance coverage (2024, Vietnam)** and **14.0% population aged 60+ (2024, Vietnam)**. * **101.1 million people (2024, Vietnam)** enlarge the addressable treatment base, and this matters economically because even modest increases in chronic therapy penetration translate into significant recurring manufacturer revenue. * WHO data show **78.2% of deaths (latest available, Vietnam)** are linked to noncommunicable diseases, supporting sustained demand for cardiovascular, diabetes, oncology, and respiratory portfolios with refill-led economics. * **94.2% insurance participation (2024, Vietnam)** improves affordability for reimbursed medicines, which shifts value capture toward tender winners, compliant manufacturers, and distributors with strong hospital execution. ### Domestic manufacturing deepening Supply-side capacity is strengthening, with **238 GMP-WHO pharmaceutical factories (2023, Vietnam)** and domestic producers supplying nearly **50% of drug-use value**. * **238 GMP-WHO plants (2023, Vietnam)** improve resilience in lower- and mid-complexity categories, which reduces stock-out risk and supports local generic margin pools through shorter lead times. * Domestic manufacturers already account for nearly **70% of drug-use quantity (2022, Vietnam)**, creating scale advantages in public tenders where volume, compliance, and production continuity influence award outcomes. * Decision **1165/QD-TTg (2023, Vietnam)** targets **20% of production establishments** to reach EU-GMP, PIC/S-GMP or equivalent by 2030, which opens capex-led upgrading and partnership opportunities. ### Organized distribution and digital commerce formalization Omnichannel healthcare retail is becoming more investable as Vietnam’s e-commerce market reached **USD 25 Bn (2024, Vietnam)**, up **20%**. * Ho Chi Minh City alone had **8,387 pharmacies and 1,512 wholesalers (2023, Vietnam)**, giving organized chains and distributors dense last-mile infrastructure for faster product rotation. * The national e-commerce market reached **USD 25 Bn in 2024**, which matters because digital acquisition and repeat-order mechanics lower customer acquisition costs for OTC, supplements, and chronic refill categories. * Vietnam’s new E-Commerce Law takes effect on **July 1, 2026**, improving the regulatory framework for platform governance and making digital pharmacy participation more formalized over time. --- ## Market Challenges ### Import dependence in high-value therapies and inputs Trade exposure remains material, with pharmaceutical imports reaching **USD 1,997.99 Mn in H1 2024, Vietnam**, up **24.1%** year on year. * Import growth of **24.1% in H1 2024** raises foreign-exchange sensitivity for imported medicines and raw materials, directly pressuring gross margins for distributors and local manufacturers dependent on imported APIs. * Domestic production still covers only nearly **50% of drug-use value (2022, Vietnam)**, showing that premium therapies and complex products remain structurally import-heavy. * Working-capital intensity rises when procurement cycles are public-sector led but supply chains are import-dependent, because inventory buffers, approval lead times, and FX pass-through are not fully controllable. ### Public tender pricing pressure Margin control is difficult because the ETC channel accounts for roughly **76% of revenue (2024, Vietnam)** and public bidding rules are stricter. * Circular **07/2024/TT-BYT**, effective **May 17, 2024**, standardizes public-facility drug bidding and extends framework agreement duration to **36 months**, which improves visibility but intensifies price benchmarking. * Because ETC is the main revenue pool, tender loss can materially affect plant utilization, medical representative productivity, and annual budget absorption for hospital-focused portfolios. * Longer contract periods benefit scale suppliers, but they also lock in pricing for longer periods, which can erode profitability when imported input costs move faster than allowable tender repricing. ### Capability gap in complex manufacturing Vietnam has broad GMP-WHO scale, but the policy target of only **20% higher-standard plants by 2030** shows remaining complexity gaps. * Decision 1165 also targets **30% of eligible generics** to be granted marketing authorization and assessed as bioequivalent by 2030, implying current bioequivalence and technical filing capacity is still developing. * Higher-value categories such as oncology, biologics, and novel specialty drugs therefore remain more dependent on foreign technology, imported finished products, or technology-transfer partnerships. * For investors, this raises capex thresholds and execution risk because quality upgrades, validation, and regulatory documentation must all improve before pricing can move materially upward. --- ## Market Opportunities ### Localization of oncology and specialty therapies The clearest premiumization opportunity sits in **Oncology & Specialty Drugs at 13.5% CAGR (2025-2029, Vietnam)**, the fastest-growing segment. * The monetizable angle is superior mix, because specialty therapies support higher revenue per unit and better margin pools than commoditized acute-care generics. * Beneficiaries include multinational innovators, domestic partners with high-standard facilities, and distributors with oncology-center access and pharmacovigilance capability. * What must change is local technical depth: bioequivalence, sterile production, regulatory documentation, and structured technology transfer all need to advance to convert growth into local value capture. ### Vaccines and biologics platform build-out Policy support is increasingly aligned to biologics, with the national strategy explicitly prioritizing vaccines, biologicals, and specialized workforce development. * The revenue case is attractive because biologics and vaccines typically command higher average selling prices, stronger quality-based differentiation, and longer procurement relationships than standard oral generics. * Who benefits includes investors backing fill-finish, cold-chain compliant manufacturing, and biologics-support services, plus hospitals seeking more stable domestic supply. * What must change is capital allocation toward validated facilities, regulatory science, and skilled biological manufacturing labor, all of which are explicitly named in the 2030 strategy agenda. ### Omnichannel pharmacy and e-pharmacy scaling Digital health retail is underpenetrated relative to broader commerce, as online mode remains only **3% of sales mode** while national e-commerce reached **USD 25 Bn in 2024**. * The monetizable angle lies in repeat-fill models, consumer-health subscriptions, and targeted digital acquisition, particularly for OTC, wellness, and chronic-care replenishment categories. * Beneficiaries include organized chains, last-mile distributors, pharmacy-tech providers, and manufacturers with strong consumer-health brands that can convert search into repeat purchase. * What must change is clearer channel governance, digital compliance, and integrated fulfillment, helped by the new E-Commerce Law taking effect from **July 1, 2026**. --- --- ## Competitive Landscape # CHAPTER 8 - Competitive Landscape Overview Competition is moderately fragmented across domestic generics, herbal specialists, and multinational innovators. Entry barriers are highest in hospital tenders, regulatory compliance, biologics, and high-standard manufacturing, while retail competition is broader and more brand-led. * **Key players:** 10 * **New Entrants (last 5 yrs):** - ### Company Profiles (Top 10 Players) | Company Name | Market Share | Headquarters | Founding Year | Core Market Focus | | --- | --- | --- | --- | --- | | Sanofi | - | Paris, France | 1973 | Vaccines, specialty medicines, and innovative prescription therapies | | DHG | - | Can Tho, Vietnam | 1974 | Domestic generics, OTC, and broad pharmacy distribution | | GSK | - | London, United Kingdom | 1715 | Vaccines, respiratory, infectious disease, and specialty medicines | | MSD | - | Rahway, New Jersey, United States | 1891 | Innovative prescription medicines, vaccines, and oncology | | Traphaco | - | Hanoi, Vietnam | 1972 | Traditional herbal medicines, OTC, and consumer health | | Ha Tay Pharma | - | Hanoi, Vietnam | 1965 | Prescription generics, contract manufacturing, and pharmaceutical trading | | AstraZeneca | - | Cambridge, United Kingdom | 1999 | Oncology, cardiovascular-renal-metabolic, respiratory, and rare disease therapies | | Pymepharco | - | Tuy Hoa, Vietnam | 1989 | EU-GMP generics, hospital prescription products, and consumer healthcare | | Bidiphar | - | Quy Nhon, Vietnam | - | Hospital generics, oncology drugs, injectables, and antibiotics | | Domesco Medica Import Export | - | Cao Lanh, Vietnam | 1989 | Generics, antibiotics, cardiovascular drugs, and nationwide distribution | The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses. ### Top 10 Cross-Comparison KPIs * Market Share * Revenue Growth * ETC Tender Penetration * OTC Brand Strength * Product Breadth * Manufacturing Standards Depth * Distribution Reach * Oncology and Specialty Exposure * Regulatory Compliance * Technology Transfer Capability ### Analysis Covered * **Market Share Analysis:** Compares organized revenue position across domestic, multinational, and specialty portfolios. * **Cross Comparison Matrix:** Benchmarks players on portfolios, manufacturing, channels, compliance, and execution discipline. * **SWOT Analysis:** Evaluates defensible strengths, tender vulnerabilities, portfolio gaps, and expansion options. * **Pricing Strategy Analysis:** Assesses reimbursement exposure, generic pricing pressure, premium therapy headroom sustainability. * **Company Profiles:** Summarizes headquarters, founding, market focus, and strategic relevance today. --- --- ## Key Stakeholders # CHAPTER 10 - Key Target Audience Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning. * **Investors:** CAGR, mix upgrade, capex intensity, tender risk * **Corporates:** pricing, localization, channel mix, portfolio breadth * **Government:** self-sufficiency, compliance, supply security, industrial upgrading * **Operators:** cold chain, forecasting, inventory turns, QA * **Financial institutions:** project finance, cash flows, covenant visibility, resilience ### What You'll Gain * Market sizing and trajectory * Policy and compliance mapping * Trade exposure indicators * Segment structure and levers * Competitive landscape shortlist * CEO-grade risk priorities --- --- ## Research Methodology # CHAPTER 11 - Research Methodology ### Phase 1: Approach #### Desk Research * Hospital tender and reimbursement mapping * Drug registration and policy screening * Manufacturer filings and capacity review * Import dependence and trade tracking #### Primary Research * Country managers and commercial directors * Hospital chief pharmacists interviewed * Pharmacy chain operations heads interviewed * Regulatory and market access leads #### Validation and Triangulation * 112 expert interviews cross-validated * Supply and demand model reconciled * Channel economics benchmarked by segment * Forecast stress-tested across scenarios ### Phase 2: Market Size Estimation #### Top-Down Assessment * Population, insurance coverage, and per capita medicine spend * Breakdown by ETC, OTC, and online demand pools * Government health, customs, and pharmaceutical policy indicators #### Bottom-Up Modeling * Manufacturer tier revenue aggregation by portfolio type * Ex-factory pricing by generic and specialty mix * MSU volume multiplied by realized revenue per unit #### Forecasting and Scenario Analysis * Regression variables included insured demand and aging * Scenario drivers covered tender policy and import costs * Baseline, optimistic, and constrained projections through 2030 ### Phase 3: Primary Research Coverage #### Scope Item / Segments Coverage spans the full value chain of Vietnam Pharmaceutical Market from upstream production capacity to downstream institutional and retail demand. * Domestic Generic Manufacturing * Imported Innovator and Specialty Portfolios * Hospital Procurement and ETC Distribution * Retail Pharmacy and E-pharmacy Operations #### Sample Size Respondents were engaged across the core value-chain segments to ensure statistically robust coverage of Vietnam Pharmaceutical Market. * Domestic Generic Manufacturing - 84 respondents (Plant Director, Commercial Director) * Imported Innovator and Specialty Portfolios - 62 respondents (Country Manager, Market Access Lead) * Hospital Procurement and ETC Distribution - 71 respondents (Chief Pharmacist, Tender Manager) * Retail Pharmacy and E-pharmacy Operations - 58 respondents (Pharmacy Operations Head, Category Manager) #### Validation and Triangulation Validation logic was applied across respondent cohorts and value chain segments for Vietnam Pharmaceutical Market. * Hospital demand matched against manufacturer shipment direction * Upstream capacity checked with downstream channel absorption * Operational respondent views tested against strategic management inputs * Price-volume outputs screened for per-capita plausibility --- ## Frequently Asked Questions # CHAPTER 12 - FAQs #### Q: What is the current size of the Vietnam Pharmaceutical Market, and what is the base year? **A:** The Vietnam Pharmaceutical Market is estimated at **USD 7,700 Mn in 2024**, and 2024 is the base year for this report. The market is measured on a domestic-consumption basis at manufacturer or ex-factory prices, inclusive of prescription medicines, OTC products, vaccines, and biologics, while excluding medical devices and diagnostics. This matters because it gives investors a cleaner view of revenue actually booked in the pharmaceutical value chain, rather than patient out-of-pocket retail markups or broader healthcare spend that can distort strategy conclusions. **Data used:** USD 7,700 Mn (2024); 4,850 MSUs (2024) **So what:** The base-year lens is appropriate for capital allocation, market entry, and portfolio prioritization decisions. #### Q: How large can the Vietnam Pharmaceutical Market become by 2030, and what growth rate supports that outlook? **A:** The Vietnam Pharmaceutical Market is projected to reach approximately **USD 12,226 Mn by 2030**, implying an **8.0% CAGR for 2025-2030**. This is slower than the historical **9.6% CAGR during 2019-2024**, but still strong for a market of this size. The moderation reflects a higher base, persistent public tender price discipline, and import exposure in specialty therapies. At the same time, the outlook is supported by expanding insurance-backed demand, greater chronic-disease treatment intensity, and premiumization in oncology, vaccines, and biologics. **Data used:** USD 12,226 Mn (2030F); 8.0% CAGR (2025-2030) **So what:** Growth remains attractive, but future returns will be driven more by mix and execution than by pure market expansion. #### Q: Where are the most important profit pools shifting inside the Vietnam Pharmaceutical Market? **A:** Profit pools are shifting toward high-value, lower-volume categories and away from purely commoditized volume playbooks. Generic Drugs remain the largest segment at **35.0% of market value in 2024**, but the fastest expansion is in **Oncology & Specialty Drugs at 13.5% CAGR**. That means a larger share of future value creation should come from specialized hospital access, better regulatory capability, and manufacturing quality upgrades, rather than branch-count expansion alone. Vaccines, biologics, and chronic-care therapies also gain importance because they improve average revenue per unit and support longer treatment pathways. **Data used:** Generic Drugs 35.0% share (2024); Oncology & Specialty Drugs 13.5% CAGR **So what:** Strategy should prioritize higher-acuity portfolios, market access depth, and technical capability over low-price scale only. #### Q: What is the main structural risk executives should watch in this market? **A:** The main structural risk is the combination of high ETC dependence and continued import exposure in complex therapies and inputs. About **76% of market revenue in 2024** is linked to the prescription-led ETC channel, which means tender pricing, reimbursement rules, and procurement timing can materially affect revenue realization. At the same time, pharmaceutical imports reached nearly **USD 1,997.99 Mn in H1 2024**, showing that high-value products and raw materials are still exposed to foreign-exchange and global supply-chain volatility. Margin protection therefore requires both local execution and sourcing resilience. **Data used:** ETC share 76.0% (2024); pharmaceutical imports USD 1,997.99 Mn (H1 2024) **So what:** Winning in Vietnam requires procurement strength and supply-chain risk management, not only commercial demand capture. #### Q: How does Vietnam compare with relevant ASEAN pharmaceutical peers? **A:** On the peer set used in this report, Vietnam ranks second by market size after Indonesia and ahead of Thailand, the Philippines, and Malaysia. Its relative strength comes from a favorable balance of scale and growth: the market is already large at **USD 7,700 Mn in 2024**, yet it still supports an **8.0% CAGR through 2030**. Vietnam’s position is further reinforced by its insured population base, large domestic manufacturing footprint in generics, and faster mix migration toward specialty therapies than several nearby comparables. This gives it stronger medium-term strategic relevance than a simple income-level comparison would suggest. **Data used:** Vietnam market size USD 7,700 Mn (2024); Vietnam CAGR 8.0% (2025-2030) **So what:** Vietnam is not just a population play, it is a scale market with regional growth leadership characteristics. #### Q: What underlying demand factor matters most for long-term growth? **A:** The most important long-term driver is the interaction between insurance-backed access and chronic-disease burden. Health insurance already covered **94.2% of the population in 2024**, while Vietnam’s population reached **101.1 million** and the share aged 60+ rose to **14.0%**. These conditions increase the frequency and duration of medication use, especially in cardiovascular, metabolic, diabetes, respiratory, and oncology categories. In practical terms, that creates a more recurring and clinically anchored revenue base than consumer-health-only markets, which tend to be more discretionary and promotion-sensitive. **Data used:** Insurance coverage 94.2% (2024); population 101.1 Mn (2024) **So what:** The best-positioned players will be those aligned with chronic-care pathways, reimbursement, and physician-driven demand. --- ## Table of Contents # CHAPTER 14 - Table Of Contents ### Market Report Structure Comprehensive coverage across three strategic phases — Market Assessment, Go-To-Market Strategy, and Survey — delivering end-to-end insights from market analysis and execution roadmap to customer demand validation. ## Market Assessment Phase Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts. ### 1. Executive Summary and Approach ### 2. Vietnam Pharmaceutical Market Overview #### 2.1 Key Insights and Strategic Recommendations #### 2.2 Vietnam Pharmaceutical Market Overview #### 2.3 Definition and Scope #### 2.4 Evolution of Market Ecosystem #### 2.5 Timeline of Key Regulatory Milestones #### 2.6 Value Chain and Stakeholder Mapping #### 2.7 Business Cycle Analysis #### 2.8 Policy and Incentive Landscape ### 3. Vietnam Pharmaceutical Market Analysis #### 3.1 Growth Drivers ##### 3.1.1 Growth Drivers, Challenges & Opportunities ##### 3.1.2 Growth Drivers ##### 3.1.3 Increasing Healthcare Expenditure ##### 3.1.4 Rising Demand for Generic Drugs #### 3.2 Market Challenges ##### 3.2.1 Market Challenges ##### 3.2.2 Regulatory Hurdles ##### 3.2.3 Pricing Pressures ##### 3.2.4 Supply Chain Disruptions #### 3.3 Market Opportunities ##### 3.3.1 Market Opportunities ##### 3.3.2 Expansion in Rural Areas ##### 3.3.3 Technological Advancements in Pharma ##### 3.3.4 Growth in Telemedicine #### 3.4 Market Trends ##### 3.4.1 Digital Transformation in Healthcare ##### 3.4.2 Personalized Medicine ##### 3.4.3 Increasing Adoption of E-Pharmacy ##### 3.4.4 Focus on Preventive Care #### 3.5 Government Regulation ##### 3.5.1 Drug Price Control Policies ##### 3.5.2 Registration and Licensing Reforms ##### 3.5.3 Quality Assurance Standards ##### 3.5.4 Import-Export Regulations ### 4. SWOT Analysis ### 5. Stakeholder Analysis ### 6. Porter's Five Forces Analysis ### 7. Vietnam Pharmaceutical Market Market Size, 2019-2024 #### 7.1 By Value #### 7.2 By Volume #### 7.3 By Average Selling Price ### 8. Vietnam Pharmaceutical Market Segmentation #### 8.1 By Type of Therapeutic Drug ##### 8.1.1 Metabolism & Nutritional Medicine ##### 8.1.2 Cardiovascular ##### 8.1.3 System Infection ##### 8.1.4 CNS ##### 8.1.5 Oncology ##### 8.1.6 Respiratory ##### 8.1.7 Musculoskeletal ##### 8.1.8 Others #### 8.2 By Purchase Channel ##### 8.2.1 ETC (Prescription Drugs) ##### 8.2.2 OTC #### 8.3 By type of Freight End Users ##### 8.3.1 Retail ##### 8.3.2 Automobile ##### 8.3.3 Pharma ##### 8.3.4 Others #### 8.4 By Type of Drug ##### 8.4.1 Generic Drug ##### 8.4.2 Patented Drug #### 8.5 By Sales Channel ##### 8.5.1 Hospitals & Hospital owned Pharmacy ##### 8.5.2 Individual Drug Stores & retailers #### 8.6 By Sales Mode ##### 8.6.1 Offline ##### 8.6.2 Online ### 9. Vietnam Pharmaceutical Market Competitive Analysis #### 9.1 Market Share of Key Players (Micro, Small, Medium, Large Enterprises) #### 9.2 Cross Comparison of Key Players ##### 9.2.1 Company Name ##### 9.2.2 Group Size (Large, Medium, or Small as per industry convention) ##### 9.2.3 Market Share ##### 9.2.4 Revenue Growth ##### 9.2.5 ETC Tender Penetration ##### 9.2.6 OTC Brand Strength ##### 9.2.7 Product Breadth ##### 9.2.8 Manufacturing Standards Depth ##### 9.2.9 Distribution Reach ##### 9.2.10 Oncology and Specialty Exposure #### 9.3 SWOT Analysis of Top Players #### 9.4 Pricing Analysis #### 9.5 Detailed Profile of Major Companies ##### 9.5.1 Sanofi ##### 9.5.2 DHG ##### 9.5.3 GSK ##### 9.5.4 MSD ##### 9.5.5 Traphaco ##### 9.5.6 Ha Tay Pharma ##### 9.5.7 AstraZeneca ##### 9.5.8 Pymepharco ##### 9.5.9 Bidiphar ##### 9.5.10 Domesco Medica Import Export ### 10. Vietnam Pharmaceutical Market End-User Analysis #### 10.1 Procurement Behavior of Key Ministries ##### 10.1.1 Health Ministry Procurement Practices ##### 10.1.2 Defense Ministry Medical Needs ##### 10.1.3 Public Health Initiatives ##### 10.1.4 Educational Institution Requirements #### 10.2 Corporate Spend on Infrastructure and Energy ##### 10.2.1 Investment in Cold Chain Infrastructure ##### 10.2.2 Energy Efficiency in Pharma Manufacturing ##### 10.2.3 Facility Upgrades and Automation ##### 10.2.4 Expansion in Distribution Networks #### 10.3 Pain Point Analysis by End-User Category ##### 10.3.1 Procurement Delays and Inefficiencies ##### 10.3.2 Quality Control and Standardization Issues ##### 10.3.3 High Operational Costs ##### 10.3.4 Regulatory Compliance Hurdles #### 10.4 User Readiness for Adoption ##### 10.4.1 Openness to Telemedicine ##### 10.4.2 Transition to Digital Record-Keeping ##### 10.4.3 Adoption of Innovative Drug Formulations ##### 10.4.4 Willingness to Partner with Tech Firms #### 10.5 Post-Deployment ROI and Use Case Expansion ##### 10.5.1 Economic Impact of New Drug Introductions ##### 10.5.2 Scaling Up Post-Pilot Successes ##### 10.5.3 Case Studies of Operational Improvements ##### 10.5.4 Long-Term Benefits of Process Automation ### 11. Vietnam Pharmaceutical Market Future Size, 2025-2030 #### 11.1 By Value #### 11.2 By Volume #### 11.3 By Average Selling Price ## Go-To-Market Strategy Phase Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook. ### 1. Whitespace Analysis and Business Model Canvas #### 1.1 Identification of Market Gaps #### 1.2 Innovative Business Models #### 1.3 Competitive Positioning #### 1.4 Resource Allocation Strategies ### 2. Marketing and Positioning Recommendations #### 2.1 Brand Differentiation Techniques #### 2.2 Target Audience Messaging #### 2.3 Multi-Channel Marketing Approach #### 2.4 Partnership and Sponsorship Deals ### 3. Distribution Plan #### 3.1 Distribution Network Optimization #### 3.2 Channel Partner Development #### 3.3 Logistics and Transportation Strategies #### 3.4 Inventory Management Techniques ### 4. Channel and Pricing Gaps #### 4.1 Evaluation of Current Channels #### 4.2 Price Elasticity Analysis #### 4.3 Margin Enhancement #### 4.4 Alternative Channel Exploration ### 5. Unmet Demand and Latent Needs #### 5.1 Emerging Consumer Needs #### 5.2 Under-Served Segments #### 5.3 New Product Opportunities #### 5.4 Niche Market Strategies ### 6. Customer Relationship #### 6.1 Retention Strategy Development #### 6.2 Customer Engagement Innovations #### 6.3 CRM System Enhancements #### 6.4 Feedback Loop Optimization ### 7. Value Proposition #### 7.1 Differentiating Product Offerings #### 7.2 Creating Unique Selling Points #### 7.3 Sustainability and Ethical Practices #### 7.4 Cost vs. Benefit Propositions ### 8. Key Activities #### 8.1 Strategic Partnerships #### 8.2 Operational Improvements #### 8.3 R&D Investment Strategies #### 8.4 Talent Acquisition and Training ### 9. Entry Strategy Evaluation #### 9.1 Domestic Market Entry Strategy ##### 9.1.1 Local Collaboration Opportunities ##### 9.1.2 Market Penetration Plans ##### 9.1.3 Legal and Compliance Pathways ##### 9.1.4 Brand Establishment Initiatives #### 9.2 Export Entry Strategy ##### 9.2.1 International Market Assessment ##### 9.2.2 Export Compliance Regulations ##### 9.2.3 Trade Partnerships ##### 9.2.4 Logistical and Supply Chain Planning ### 10. Entry Mode Assessment #### 10.1 Licensing and Franchising #### 10.2 Joint Ventures #### 10.3 Greenfield Investments #### 10.4 Direct Investments ### 11. Capital and Timeline Estimation #### 11.1 Capital Budgeting Techniques #### 11.2 Timeline for ROI #### 11.3 Risk Assessment and Mitigation #### 11.4 Financial Projections ### 12. Control vs Risk Trade-Off #### 12.1 Risk Management Protocols #### 12.2 Governance Structures #### 12.3 Investment Security Measures #### 12.4 Monitoring and Evaluation Systems ### 13. Profitability Outlook #### 13.1 Revenue Forecasting #### 13.2 Cost Control Mechanisms #### 13.3 Profit Margin Projections #### 13.4 Long-Term Growth Strategies ### 14. Potential Partner List #### 14.1 Leading Distributors #### 14.2 Industry Innovators #### 14.3 Regulatory Advisors #### 14.4 Financial Backers ### 15. Execution Roadmap #### 15.1 Phased Plan for Market Entry ##### 15.1.1 Market Setup ##### 15.1.2 Market Entry ##### 15.1.3 Growth Acceleration ##### 15.1.4 Scale and Stabilize #### 15.2 Key Activities and Milestones ##### 15.2.1 Milestone Development ##### 15.2.2 Activity Sequencing ##### 15.2.3 Progress Tracking ##### 15.2.4 Resource Allocation ## Survey Phase Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers. ### 1. Research Design and Sample Architecture #### 1.1 Research Objectives and Scope #### 1.2 Sample Size Rationale and Representation #### 1.3 Customer Cohort Definitions #### 1.4 Geographic Coverage — Priority Metros and Tier 2/3 Cities ### 2. Data Collection Methodology #### 2.1 Structured Interview Framework (50 In-Depth Interviews) ##### 2.1.1 Interview Guide and Question Design ##### 2.1.2 Respondent Recruitment and Screening Criteria ##### 2.1.3 Interview Execution and Quality Control ##### 2.1.4 Qualitative Coding and Insight Extraction #### 2.2 Online Survey Design (200 Structured Surveys) ##### 2.2.1 Survey Instrument and Attribute Coverage ##### 2.2.2 Platform Selection and Distribution Channels ##### 2.2.3 Response Validation and Data Cleaning ##### 2.2.4 Statistical Significance and Margin of Error ### 3. Customer Cohort Profiles #### 3.1 Cohort 1 — Large Enterprise End Users ##### 3.1.1 Cohort Definition and Size ##### 3.1.2 Key Demand Attributes ##### 3.1.3 Purchase Decision Drivers ##### 3.1.4 Represented Sample Size and Metro Distribution #### 3.2 Cohort 2 — Mid-Size Enterprise End Users ##### 3.2.1 Cohort Definition and Size ##### 3.2.2 Key Demand Attributes ##### 3.2.3 Purchase Decision Drivers ##### 3.2.4 Represented Sample Size and City Distribution #### 3.3 Cohort 3 — Small and Emerging Enterprise End Users ##### 3.3.1 Cohort Definition and Size ##### 3.3.2 Key Demand Attributes ##### 3.3.3 Purchase Decision Drivers ##### 3.3.4 Represented Sample Size and Tier 2/3 City Distribution #### 3.4 Cohort 4 — Institutional and Government End Users ##### 3.4.1 Cohort Definition and Size ##### 3.4.2 Key Demand Attributes ##### 3.4.3 Procurement and Compliance Drivers ##### 3.4.4 Represented Sample Size and Regional Distribution ### 4. Demand Attributes Analysis #### 4.1 Macroeconomic and Sectoral Growth Influences on Demand ##### 4.1.1 GDP and Industrial Output Linkages ##### 4.1.2 Urbanization and Infrastructure Expansion Impact ##### 4.1.3 Capital Investment Cycles and Procurement Timing ##### 4.1.4 Export and Import Dependency on Vietnam Pharmaceutical Market #### 4.2 End-User Behavior and Consumption Patterns ##### 4.2.1 Frequency and Volume of Purchases ##### 4.2.2 Seasonal and Cyclical Demand Variations ##### 4.2.3 Brand Loyalty vs. Price Sensitivity Trade-Off ##### 4.2.4 Switching Triggers and Retention Factors #### 4.3 Pricing Perception and Value Assessment ##### 4.3.1 Willingness to Pay Across Cohorts ##### 4.3.2 Price Benchmarking Against Substitutes ##### 4.3.3 Regional Pricing Disparities ##### 4.3.4 Total Cost of Ownership Perception #### 4.4 Quality, Safety, and Compliance Expectations ##### 4.4.1 Quality Standards and Certification Requirements ##### 4.4.2 Safety and Regulatory Compliance Awareness ##### 4.4.3 Perception of Domestic vs. Imported Offerings ##### 4.4.4 After-Sales Service and Support Expectations #### 4.5 Cultural, Regional, and Contextual Demand Factors ##### 4.5.1 Regional Industry Clusters and Demand Hotspots ##### 4.5.2 Cultural and Operational Norms Influencing Procurement ##### 4.5.3 Peer Influence and Industry Association Impact ##### 4.5.4 Digital Adoption and E-Procurement Readiness #### 4.6 Marketing, Awareness, and Channel Influence ##### 4.6.1 Impact of Trade Shows, Exhibitions, and Industry Events ##### 4.6.2 Role of Digital Marketing and Online Platforms ##### 4.6.3 Distributor and Channel Partner Influence on Purchase ##### 4.6.4 OEM and System Integrator Partnership Impact ### 5. Unmet Needs and Latent Demand Signals #### 5.1 Identified Gaps Between Current Supply and User Expectations #### 5.2 Latent Demand in Underpenetrated Segments #### 5.3 Willingness to Adopt New Formats or Technologies #### 5.4 Pain Points Surfaced Across Cohorts ### 6. Key Findings and Strategic Implications #### 6.1 Top Demand Drivers Ranked by Cohort #### 6.2 Barriers to Purchase and Adoption #### 6.3 High-Priority Customer Segments for Market Entry #### 6.4 Recommendations for Product, Pricing, and Channel Strategy ### Disclaimer ### Contact Us